Evidence map›Paper›PMID 42709211›Full record

ArticleCurrent microbiology2026

Caerin 1.1/1.9 Inhibits Growth and Biofilm Formation of Carbapenem-Resistant Klebsiella pneumoniae and Induces Coordinated Transcriptomic Stress Responses.

Zhijun Lin, Quanlan Fu, Junjie Li, Jinyi Wu, Hongyin Wu, Yongxin Liang, Yuandong Luo, Wei Yang, Hejie Li, Tianfang Wang and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Current microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Zhijun LinMedical College, Guizhou University, Guiyang, 550025, China.
Quanlan FuZhongao Biomedical Technology (Guangdong) Co. Ltd, Zhongshan, 528400, China.
Junjie LiZhongao Biomedical Technology (Guangdong) Co. Ltd, Zhongshan, 528400, China.
Jinyi WuThe First Affiliated Hospital, Clinical Medical School, Guangdong Pharmaceutical University, Guangzhou, 510080, China.
Hongyin WuThe First Affiliated Hospital, Clinical Medical School, Guangdong Pharmaceutical University, Guangzhou, 510080, China.
Yongxin LiangZhongao Biomedical Technology (Guangdong) Co. Ltd, Zhongshan, 528400, China.
Yuandong LuoZhongao Biomedical Technology (Guangdong) Co. Ltd, Zhongshan, 528400, China.
Wei YangGuiyang Hospital of Stomatology, Guiyang, 550025, Guizhou Province, China.
Hejie LiSchool of Science, Technology and Engineering, University of the Sunshine Coast, Maroochydore, QLD, 4558, Australia.
Tianfang WangSchool of Science, Technology and Engineering, University of the Sunshine Coast, Maroochydore, QLD, 4558, Australia. twang@usc.edu.au.
Guoying NiZhongao Biomedical Technology (Guangdong) Co. Ltd, Zhongshan, 528400, China. 357303070@qq.com.
Xiaosong LiuMedical College, Guizhou University, Guiyang, 550025, China. xiaosongl@yahoo.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Carbapenem-resistant Klebsiella pneumoniae (CRKP) is a major cause of healthcare-associated infections and a World Health Organization critical-priority pathogen due to extensive antimicrobial resistance and limited treatment options. Host-defense peptides represent promising alternatives to conventional antibiotics because of their broad-spectrum activity and low propensity for resistance development. Here, we evaluated the antibacterial activity of a fixed 1:1 combination of the frog-derived peptides caerin 1.1 and caerin 1.9 (F1/F3) against a reference K. pneumoniae strain and four clinical CRKP isolates. Individually, F1 and F3 exhibited MICs of 12 µM against the reference strain, whereas the F1/F3 combination reduced the MIC to 5 µM and showed an additive antibacterial interaction. F1/F3 retained activity against clinical CRKP isolates with strain-dependent susceptibility and inhibited biofilm formation and reduced pre-established biofilm biomass in a concentration-dependent manner. Scanning electron microscopy revealed pronounced morphological and surface alterations following peptide treatment. Transcriptomic analysis demonstrated broad bacterial responses to F1/F3 exposure, including downregulation of genes associated with ribosomal function, protein synthesis, metabolism, and oxidative phosphorylation, together with activation of stress-response pathways and differential expression of predicted small regulatory RNAs. SNP analysis revealed no evidence of increased mutation burden following peptide exposure. These findings demonstrate the antibacterial potential of F1/F3 against CRKP and provide insights into bacterial responses associated with caerin peptide treatment.

Indexed as

Anti-Bacterial AgentsBiofilmsCarbapenem-Resistant EnterobacteriaceaeKlebsiella pneumoniaeTranscriptomeCarbapenemsGene Expression ProfilingGene Expression Regulation, BacterialHumansKlebsiella InfectionsMicrobial Sensitivity TestsStress, PhysiologicalAnti-Bacterial AgentsCarbapenems

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.